Spots Global Cancer Trial Database for Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
Official Title: A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer
Study ID: NCT00625846
Conditions
Study Description
Brief Summary: This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor.
Detailed Description: PRIMARY OBJECTIVE: I. To establish the safety and efficacy of GW786034 (pazopanib hydrochloride) as a therapeutic in patients afflicted with differentiated, medullary and anaplastic thyroid cancers. CORRELATIVE OBJECTIVES: I. Assessment of the impact of therapy with GW786034 on serum/plasma vascular endothelial growth factor (VEGF) levels. II. To explore the potential relationship between changes in thyroglobulin levels and tumor response in patients with advanced differentiated thyroid cancer known to be thyroglobulin antibody negative. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for up to 3 years after registration.
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
University of Colorado Hospital, Aurora, Colorado, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Fairview Ridges Hospital, Burnsville, Minnesota, United States
Fairview-Southdale Hospital, Edina, Minnesota, United States
Unity Hospital, Fridley, Minnesota, United States
Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States
Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States
Mayo Clinic, Rochester, Minnesota, United States
Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States
United Hospital, Saint Paul, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Chinese University of Hong Kong-Prince of Wales Hospital, Shatin, Hong Kong, China
National University Hospital Singapore, Singapore, , Singapore
National Cancer Centre, Singapore, , Singapore
Johns Hopkins Singapore, Singapore, , Singapore
National Taiwan University Hospital, Taipei, , Taiwan
Contact Details
Name: Keith C Bible
Affiliation: Mayo Clinic
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
